Immunotherapy in Hepatocellular Carcinoma
Based on this evidence, a deep understanding of the immunological status and biological targets modulating immunological microenvironments should be quite informative for the development of future immunotherapy in HCC. From this point of view, this Special Issue will highlight the current state of t...
Saved in:
| Other Authors: | , |
|---|---|
| Format: | Electronic Book Chapter |
| Language: | English |
| Published: |
Basel
MDPI - Multidisciplinary Digital Publishing Institute
2023
|
| Subjects: | |
| Online Access: | DOAB: download the publication DOAB: description of the publication |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000naaaa2200000uu 4500 | ||
|---|---|---|---|
| 001 | doab_20_500_12854_100022 | ||
| 005 | 20230511 | ||
| 003 | oapen | ||
| 006 | m o d | ||
| 007 | cr|mn|---annan | ||
| 008 | 20230511s2023 xx |||||o ||| 0|eng d | ||
| 020 | |a books978-3-0365-6690-0 | ||
| 020 | |a 9783036566917 | ||
| 020 | |a 9783036566900 | ||
| 040 | |a oapen |c oapen | ||
| 024 | 7 | |a 10.3390/books978-3-0365-6690-0 |c doi | |
| 041 | 0 | |a eng | |
| 042 | |a dc | ||
| 072 | 7 | |a M |2 bicssc | |
| 072 | 7 | |a MJCL |2 bicssc | |
| 100 | 1 | |a Nishida, Naoshi |4 edt | |
| 700 | 1 | |a Kudo, Masatoshi |4 edt | |
| 700 | 1 | |a Nishida, Naoshi |4 oth | |
| 700 | 1 | |a Kudo, Masatoshi |4 oth | |
| 245 | 1 | 0 | |a Immunotherapy in Hepatocellular Carcinoma |
| 260 | |a Basel |b MDPI - Multidisciplinary Digital Publishing Institute |c 2023 | ||
| 300 | |a 1 electronic resource (276 p.) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 506 | 0 | |a Open Access |2 star |f Unrestricted online access | |
| 520 | |a Based on this evidence, a deep understanding of the immunological status and biological targets modulating immunological microenvironments should be quite informative for the development of future immunotherapy in HCC. From this point of view, this Special Issue will highlight the current state of the art in the immunotherapy of HCC from both the basic and clinical perspectives, and outline future perspectives for improving therapies. | ||
| 540 | |a Creative Commons |f https://creativecommons.org/licenses/by/4.0/ |2 cc |4 https://creativecommons.org/licenses/by/4.0/ | ||
| 546 | |a English | ||
| 650 | 7 | |a Medicine |2 bicssc | |
| 650 | 7 | |a Oncology |2 bicssc | |
| 653 | |a cancer immunotherapy | ||
| 653 | |a TCGA | ||
| 653 | |a mutations | ||
| 653 | |a copy number variations | ||
| 653 | |a microRNAs | ||
| 653 | |a PD-1 | ||
| 653 | |a PD-L1 | ||
| 653 | |a hepatocellular carcinoma | ||
| 653 | |a predictive factors | ||
| 653 | |a immunotherapy | ||
| 653 | |a immune checkpoint inhibition | ||
| 653 | |a check-point inhibitors | ||
| 653 | |a liver disease | ||
| 653 | |a outcome | ||
| 653 | |a biomarkers | ||
| 653 | |a combination immunotherapy | ||
| 653 | |a immune-related adverse events (irAEs) | ||
| 653 | |a hepatocellular carcinoma (HCC) | ||
| 653 | |a alpha fetoprotein response | ||
| 653 | |a immune checkpoint inhibitor | ||
| 653 | |a unresectable hepatocellular carcinoma | ||
| 653 | |a a disintegrin and metalloprotease 9 | ||
| 653 | |a nivolumab | ||
| 653 | |a natural killer | ||
| 653 | |a CTLA-4 | ||
| 653 | |a combination therapy | ||
| 653 | |a PD-1 antibody | ||
| 653 | |a PD-L1 antibody | ||
| 653 | |a anti-VEGF inhibitor | ||
| 653 | |a molecular classification | ||
| 653 | |a immune phenotype | ||
| 653 | |a stem cell marker | ||
| 653 | |a oncogenic signal | ||
| 653 | |a β-catenin | ||
| 653 | |a genetic alteration | ||
| 653 | |a liver cancer | ||
| 653 | |a effectiveness | ||
| 653 | |a safety | ||
| 653 | |a HCC | ||
| 653 | |a molecular-targeted agent | ||
| 653 | |a TACE | ||
| 653 | |a tyrosine kinase inhibitor | ||
| 653 | |a CD14+ cells | ||
| 653 | |a programmed death 1 ligands | ||
| 653 | |a translational approaches | ||
| 653 | |a combination therapies | ||
| 653 | |a therapy resistance | ||
| 653 | |a predictive markers | ||
| 653 | |a tissue-resident memory CD8 T cells | ||
| 653 | |a immune checkpoint blockade | ||
| 856 | 4 | 0 | |a www.oapen.org |u https://mdpi.com/books/pdfview/book/7115 |7 0 |z DOAB: download the publication |
| 856 | 4 | 0 | |a www.oapen.org |u https://directory.doabooks.org/handle/20.500.12854/100022 |7 0 |z DOAB: description of the publication |